Ketabon To Present Advancements In At-Home Ketamine Therapy For Treatment-Resistant Depression At American Society Of Clinical Psychopharmacology Annual Meeting
May 21, 2024 08:30 ET
|
HMNC Holding GmbH
MUNICH, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- Ketabon GmbH (“Ketabon” or “the Company”), a joint venture between HMNC Brain Health and Develco Pharma, announced today the Company will present...
Head-to-head Trial of Prolonged-Release Oral Ketamine Formulation, KET01, and Intranasal SPRAVATO®, Finds Less Incidence of Dissociation or Cardiovascular Effects with Oral Treatment, at doses used for Treatment-Resistant Depression
November 13, 2023 08:00 ET
|
HMNC Holding GmbH
Results Suggest Formulation Potentially Suitable for At-Home Administration Ketabon Also Releases In-Depth Data from Phase 2 KET01 Trial MUNICH, Germany, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ketabon...
Ketabon GmbH Reports Top-Line Results from Phase 2 Trial of Take-at-Home, Oral Ketamine Option for Treatment-Resistant Depression
August 14, 2023 09:00 ET
|
HMNC Holding GmbH
Lead Asset KET01, an Oral Prolonged-Release Ketamine Formulation, Demonstrated Early Improvements in Depressive Severity Key Findings Included Minimal Incidences of Dissociation or Cardiovascular...
HMNC Brain Health to Participate in the Psychedelic Science Conference 2023 and the H.C. Wainwright & Co. 4th Annual Neuropsychiatry Conference
June 21, 2023 08:30 ET
|
HMNC Holding GmbH
MUNICH, Germany, June 21, 2023 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “company”), a global clinical-stage biopharmaceutical company, pioneering the development of personalized...
HMNC Brain Health Begins Phase 2 Study for Personalized Treatment of Stress-Axis Related Major Depressive Disorder (MDD)
June 20, 2023 08:00 ET
|
HMNC Holding GmbH
MUNICH, Germany, June 20, 2023 (GLOBE NEWSWIRE) -- HMNC Brain Health (‘‘HMNC’’ or the ‘‘Company’’), a global clinical-stage biopharmaceutical company pioneering the development of personalized...
HMNC Brain Health Appoints Evan Papanastasiou as VP Clinical Development
May 08, 2023 07:00 ET
|
HMNC Holding GmbH
MUNICH, Germany, May 08, 2023 (GLOBE NEWSWIRE) -- HMNC Brain Health (‘‘HMNC’’ or the ‘‘Company’’), a global clinical-stage biopharmaceutical company, pioneering the development of personalized...
HMNC Brain Health and Develco Pharma Announce Last Patient Being Randomized in Oral Prolonged-Release Ketamine (KET01) Trial for Treatment-Resistant Depression
March 28, 2023 08:00 ET
|
HMNC Holding GmbH
MUNICH, Germany, March 28, 2023 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC'' or the “Company”), a global clinical stage biopharmaceutical company pioneering the development of personalized...
HMNC Brain Health Raises EUR 14.3 million to Advance Precision Psychiatry Therapies
October 20, 2022 08:00 ET
|
HMNC Holding GmbH
Round Comprised of New and Former Investors, Including Dr. Josef Ackermann, Wilhelm Beier, Toni Kroos, and Carsten Maschmeyer First of Two Expected Closings of Round Increases Total Capital Raised to...
Maximilian Doebler Appointed Chief Business Officer of HMNC Brain Health
August 22, 2022 08:30 ET
|
HMNC Holding GmbH
MUNICH, Germany, Aug. 22, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC'' or the “Company”), a clinical stage precision psychiatry biopharma company, pioneering the development of personalized...
HMNC Brain Health to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond on June 27, 2022
June 23, 2022 08:00 ET
|
HMNC Holding GmbH
MUNICH, Germany, June 23, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “Company”), a global clinical stage biopharmaceutical company pioneering the development of personalized therapies...